[English]  [Pусский]  [中文]  
 
ctt-journal > Durosinmi et al. abstract

Durosinmi et al. abstract

Please cite this article as follows: Durosinmi MA, Faluyi JO, Oyekunle AA, Salawu L, Adediran IA, Akinola NO, Bamgbade OO, Okanny CC, Akanmu S, Ogbe OP, Wakama TT, Nwauche CA, Enosolease ME, Halim DNK, Bazuaye GN, Okocha CE, Olaniyi JA, Akingbola TS, Mabayoje VO, Raji AA, Mamman A, Kuliya-Gwarzo A, Ibegbulam OG, Ocheni S, Tanko Yo, Arewa OP, Bolarinwa RAA, Kassim DO, Ndakotsu MA, Amusu OA, Akinyanju OO. The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia. Cell Ther Transplant. 2008;1:e.000027.01. doi:10.3205/ctt-2008-en-000027.01

 

The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia

Prof Muheez A Durosinmi, Prof Julius O Faluyi, Dr Anthony A Oyekunle, Dr Lateef Salawu, Dr Ismail A Adediran, Dr Norah O Akinola, Oluwakemi O Bamgbade, Dr Charles C Okanny, Dr Sulaiman Akanmu, Dr Oche P Ogbe, Dr Tambi T Wakama, Dr Chijoke A Nwauche, Dr Matthew E Enosolease, Dr Daye NK Halim, Dr Godwin N Bazuaye, Dr Chide E Okocha, Dr J A Olaniyi, Dr Titi S Akingbola, Dr Victor O Mabayoje, Dr Ajani A Raji, Dr Aisha Mamman, Dr Aisha Kuliya-Gwarzo, Dr Obike G Ibegbulam, Dr Sunday Ocheni, Dr Yohanna Tanko, Dr Oladimeji P Arewa, Dr Rahman AA Bolarinwa, Dr Davidson O Kassim, Dr Mohammed A Ndakotsu, Dr Omotilewa A Amusu, Prof O O Akinyanju
Abstract

Objectives: To assess response and toxicity to Imatinib mesylate (Glivec) in Nigerian Patients with chronic myeloid leukemia.
Methods: From August 2003 to August 2007, 98 consecutive, consenting patients, 56 (57%) males and 42 (43%) females, median age 36 years (range, 11-65 years) diagnosed with  CML, irrespective of disease phase received Imatinib at a dose of 300-600mg/day at the OAU Teaching Hospitals, Nigeria. Response to therapy was assessed by clinical, haematological and cytogenetic parameters. Blood counts were checked every two weeks in the first three months of therapy. Chromosome analysis was repeated sixth monthly. Overall survival (OS) and frequency of complete or major cytogenetic remission (CCR/MCR) were evaluated.  
Results: Complete haematologic remission was achieved in 64% and 83% of patients at one and three months, respectively. With a median follow-up of 25 months, the rates of CCR and MCR were 59% and 35% respectively. At 12 months of follow-up, OS and progression- free survival (PFS) were 96% and 91%, respectively. Achievement of CR at six months was associated with significantly better survival (p = 0.043).
Conclusions: Compared to treatment outcome with conventional chemotherapy and alpha interferon, as previously used in Nigeria, the results obtained with this regimen has established Imatinib as the first-line treatment strategy in patients with CML, as it is in other populations, with minimal morbidity.

Keywords: imatinib mesylate, chronic myeloid leukemia, Nigeria, cytogenetic remission

Please cite this article as follows: Durosinmi MA, Faluyi JO, Oyekunle AA, Salawu L, Adediran IA, Akinola NO, Bamgbade OO, Okanny CC, Akanmu S, Ogbe OP, Wakama TT, Nwauche CA, Enosolease ME, Halim DNK, Bazuaye GN, Okocha CE, Olaniyi JA, Akingbola TS, Mabayoje VO, Raji AA, Mamman A, Kuliya-Gwarzo A, Ibegbulam OG, Ocheni S, Tanko Yo, Arewa OP, Bolarinwa RAA, Kassim DO, Ndakotsu MA, Amusu OA, Akinyanju OO. The use of Imatinib mesylate in Nigerians with chronic myeloid leukemia. Cell Ther Transplant. 2008;1:e.000027.01. doi:10.3205/ctt-2008-en-000027.01

Full text
<-- Previous abstract        Contents        Next abstract -->
<-- Предыдущее резюме        Oглавление        Cледующее резюме -->